[285 Pages Report] Immunostimulants are drugs that stimulate the immune system by accelerating the activity of immune cells, tissues, and organs and also help the body to fight against sepsis and diseases.
As per Future Market Insights’ latest industry analysis, the global immunostimulants market was valued at around US$ 102.2 Bn in 2021 and is anticipated to exhibit a CAGR of close to 6.2% over the forecast period (2022-2032). Against this backdrop, the market size is projected to reach US$ 108.2 Bn in 2022.
Growing prevalence of autoimmune diseases is fueling the development of immunostimulants. Around 4% of the world’s population is affected by different autoimmune diseases, which also include multiple sclerosis and rheumatoid arthritis. In the U.S., autoimmune diseases represent the third most common chronic disorder.
Market Outlook:
| Attributes | Key Statistics |
| Immunostimulants Market Base Year Value (2021) | US$ 102.2 Bn |
| Estimated Market Size (2022) | US$ 108.2 Bn |
| Projected Market Valuation (2032) | US$ 197.6 Bn |
| Value-based CAGR (2022-2032) | 6.2% |
| Market Share of Top 5 Countries | 57.5% |
Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15145
Further, demand for immunostimulants in countries such as India and China is expected to increase at a considerable pace. Developing economies are refining their healthcare framework, owing to increasing accessibility to resources, and increasing efforts by manufacturers to gain drug approvals for international retail.
For instance, in November 2021, PharmaEssentia Corporation, a company based in Taiwan, announced that the U.S. Food and Drug Administration (FDA) has approved BESREMi, long-acting interferon for the treatment of adults with polycythemia vera.
“Rising awareness regarding immunostimulants therapy for chronic diseases across emerging economies, along with increasing investments in the pharmaceutical and healthcare sectors will fuel the growth in the market over the forecast period,” says an FMI analyst.
Key Takeaways:
- Based on product type, demand for vaccines is expected to increase at a 6.4% CAGR over the forecast period.
- In terms of application, the oncology segment will account for 34.7% of the total market share by 2032.
- By end user, hospital pharmacies held 34.3% of the total market share in 2021 and the trend is expected to continue over the forecast period.
- The U.S. accounted for 92.85 of the North America immunostimulants market in 2021.
- Sales in the Germany immunostimulants market are forecast to increase at a 6.4% CAGR over the assessment period.
- Demand for immunostimulants in Japan will grow at a 6% CAGR over the forecast period.
Ask from Market Research Expert@ https://www.futuremarketinsights.com/ask-question/rep-gb-15145
Competition Landscape
Leading players operating in the global immunostimulants market are investing in acquisitions and collaborations to expand their global presence. They are also investing in research and development to improve their product portfolios.
For instance:
- In August 2021, Bayer AG acquired Vividion Therapeutics to strengthen its drug discovery platform to meet the high unmet medical needs for immune-related diseases and for oncology.
- In August 2020, Bristol Myers Squibb collaborated with Dragonfly Therapeutics and announced an exclusive global license for Dragonfly’s IL-12 investigational immunotherapy program.
Want more insights?
Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. The global immunostimulants market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the immunostimulants market segment based on by product type – (colony-stimulating factors, interferons, interleukins, and vaccines), by application- (oncology, respiratory, chronic, and autoimmune disorders, and others), by end-user (hospital pharmacies, retail pharmacies, specialty clinics, and online pharmacies), across seven major regions.
Buy Complete Report@ https://www.futuremarketinsights.com/checkout/15145
Key Market Segments Covered in Immunostimulants Industry Research
By Product:
- Colony Stimulating Factors
- Interferons
- Interleukins
- Vaccines
By Application:
- Oncology
- Respiratory
- Chronic & Autoimmune Disorders
- Others
By End-User:
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Clinics
- Online Pharmacies
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs